Avantor, Inc. (AVTR) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

Earnings Reports

• Avantor (AVTR) Q2 2026: VWR Organic Growth Turns Positive, Setting Stage for H2 Acceleration
  July 29, 2026
• Avantor (AVTR) Q4 2025: VWR Relaunch and $35M Targeted Investment Signal Strategic Channel Reset
  June 15, 2026
• Avantor (AVTR) Q1 2026: VWR Stabilizes as 25% Leadership Refresh Targets Back-Half Turnaround
  April 29, 2026
• Avantor (AVTR) Q3 2025: $785M Lab Goodwill Impairment Signals Urgent Turnaround Push
  October 29, 2025
• Avantor (AVTR) Q2 2025: $100M Share Gains Offset by Margin Compression as Pricing War Intensifies
  August 01, 2025
• Avantor (AVTR) Q1 2025: Cost Transformation Target Lifted to $400M as Lab Solutions Stalls
  July 06, 2025
• Avantor (AVTR) Q3 2024: Free Cash Flow Guidance Raised 20% as Bioprocessing Orders Accelerate
  October 25, 2024
• Avantor (AVTR) Q2 2024: Bioprocessing Orders Drive High-Single Digit Sequential Growth
  July 26, 2024
• Avantor (AVTR) Q1 2024: Cost Transformation Delivers $75M Savings Trajectory, Margin Ramp De-Risked
  April 26, 2024
• Avantor (AVTR) Q4 2023: $300M Cost Program Targets Margin Upside Amidst 4.8% Organic Decline
  February 14, 2024

Browse all companies